Laviana Pharma

Executive Summary

Laviana Pharma, a private Chinese biopharmaceutical company founded in 2017, specializes in discovering and developing novel small molecule therapies for oncology and immunology. With a focus on modulating the tumor microenvironment and immune response, the company aims to address significant unmet medical needs through innovative targets. Currently in the Phase 1 stage, Laviana’s pipeline includes early-stage candidates, though specific programs have not been disclosed. The company’s research is centered in Shanghai, China, and it has an estimated employee base of 50-200. Despite lacking publicly available financial data, Laviana’s strategic focus on novel mechanisms in high-demand therapeutic areas positions it as a potential player in the oncology and immunology landscape. The company’s progress will depend on successful advancement of its pipeline through preclinical and clinical milestones, funding, and partnerships.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Oncology Candidate60% success
• 2027Initiation of Phase 1 Clinical Trial for Novel Immunotherapy Target50% success
• TBDPotential Partnership or Licensing Deal for Pipeline Program40% success